Abstract | AIMS OF THE STUDY: PATIENTS AND METHODS: we reviewed 471 patients with AIDS, and we analysed 71 AIDS patients with TE, who received intravenous therapy with TMP-SMZ ( TMP: 10 mg/kg/day, SMZ: 50 mg/kg/day) for 4 weeks. RESULTS: 35 patients (49.2%) had a complete regression of clinical signs, and a complete resolution of radiological lesions was noted in 41 patients (57.7%). Improvement of clinical signs and radiological lesions were observed in 27 patients (38%), and in nine patients (12.6%), respectively. In contrast, nine patients (12.6%) did not show any clinical change, or worsened. Twenty-two patients (30.9%) suffered from adverse cutaneous reactions, whereas many patients had haematological toxicity. CONCLUSIONS:
TMP-SMZ seems to be an efficient therapy for TE in AIDS patients, although further prospective, randomized therapeutic trials are required to confirm these results.
|
Authors | D Torre, F Speranza, R Martegani, C Zeroli, M Banfi, M Airoldi |
Journal | The Journal of infection
(J Infect)
Vol. 37
Issue 1
Pg. 15-8
(Jul 1998)
ISSN: 0163-4453 [Print] England |
PMID | 9733371
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Infective Agents
- Trimethoprim, Sulfamethoxazole Drug Combination
|
Topics |
- AIDS-Related Opportunistic Infections
(drug therapy, parasitology)
- Adult
- Anti-Infective Agents
(administration & dosage, adverse effects, therapeutic use)
- Female
- Humans
- Male
- Retrospective Studies
- Toxoplasmosis, Cerebral
(drug therapy, mortality)
- Treatment Outcome
- Trimethoprim, Sulfamethoxazole Drug Combination
(administration & dosage, adverse effects, therapeutic use)
|